Expect Shengyi to enter Nvidia supply chain in 2024
We expect 1H24 to be still profitable
China Pharmaceutical & Healthcare: Expecting global funding recovery in the coming quarters
2Q loss reduction trend better than expectation
1H24 preview: margin weakness priced in; expect gradual ASP/margin recovery in 2H
Expect $3.5bn CB dilutive effect to be short-term
Expect domestic business to rebound from 2025
Turnaround is here but weaker than expected
China Property Sector – Property+ Weekly: Can we expect post-CNY recovery?
1H23 Preview: weak revenue amid industry headwinds; expect smartphone recovery in 2H23E